HONG KONG, Sept. 19, 2012 /PRNewswire/ -- Golden Meditech Holdings Limited ("Golden Meditech", together with its subsidiaries collectively as the "Group", 801.HK; 910801.TW), a leading integrated healthcare enterprise in China has reached agreements with certain investors which invested in China Bright Group Co. Limited ("China Bright"), non-wholly-owned medical devices subsidiary of Golden Meditech in August 2010. Under the revised agreements, the investors have agreed to expand the list of stock exchanges on which the securities of China Bright can be listed and to extend the initial public offering ("IPO") timeframe to 26 February 2014 for China Bright to seek appropriate listing opportunities under the current market conditions, and at the same time, Golden Meditech will increase its equity holding in China Bright to 80.37%.
Mr. Kam Yuen, Chairman and Chief Executive Officer of Golden Meditech, said: "With the Chinese government pursuing to work for the betterment of medical practice, a number of favourable policies have been introduced, such as the 'Level III General Hospital Accreditation and Administration Standards' implemented by the Ministry of Health which demand hospital mangers to initiate autologous blood recovery programmes to alleviate surgical blood shortage. The demand for our key products, such as autologous blood recovery system is set to rise in the future to comply with these latest government developments." Mr. Kam continued, "We consider that a separate listing of China Bright is in the best interests of the Group and the shareholders. This will allow China Bright to unlock its underlying value as well as seizing business opportunities elsewhere. The decision to extend the IPO timeframe has demonstrated commitment from investors over the value of China Bright amid market volatility. We will continue to monitor market conditions and launch the separate listing of China Bright at an appropriate time."
Notice of Conference Call
Golden Meditech will hold a conference call for analysts and investors to discuss the above-mentioned development on Wednesday, 19 September, 2012 at 8:00 pm HKT / 8:00 am EST. To participate, please dial:
| Hong Kong Tel: + 852-2475-0994 |
China Tel: 400-620-8038 or 800-819-0121 |
International Tel: 1-718-354-1231 or 1-866-519-4004 |
Access code: 30636251
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
For inquiries, please contact:
Golden Meditech Holdings Limited
Investor Relations Department
Tel: (852) 3605 8180
Fax: (852) 3605 8181
Email: ir@goldenmeditech.com